In this issue:
CCL2: a biomarker and potential therapeutic target in SSc?
JAK-1 inhibition with filgotinib: initial efficacy in RA
Baricitinib ± MTX improves pre-specified PROs
Herpes zoster + tofacitinib: risk increased with concomitant GCs
Safety, immunogenicity of live zoster vaccination prior to tofacitinib
Lesinurad + febuxostat shows promise in tophaceous gout
Long-term liver safety data with tocilizumab in RA
Maintaining vitamin D sufficiency in knee OA
Using ultrasound to predict inflammatory arthritis in arthralgia
Allopurinol vs febuxostat and incident renal disease in the elderly
Outcomes of disease activity-guided TNFi dose reduction in RA
Please login below to download this issue (PDF)